CL9

2-chloro-2'-deoxyadenosine

Created:	2008-02-18
Last modified:	2011-06-04

Find Related PDB Entry
2 entries where CL9 is found as a standalone ligand

Help Find related ligands:
Similar Ligands (Stereospecific) Similar Ligands (including Stereoisomers) Similar Ligands (Quick Screen) Similar Ligands (Substructure Stereospecific) Similar Ligands (Substructure including Stereoisomers)

Help

Find related ligands:

Similar Ligands (Stereospecific) Similar Ligands (including Stereoisomers) Similar Ligands (Quick Screen) Similar Ligands (Substructure Stereospecific) Similar Ligands (Substructure including Stereoisomers)

Chemical Details
Formal Charge	0
Atom Count	31
Chiral Atom Count	3
Bond Count	33
Aromatic Bond Count	10

Toggle Hydrogen Toggle Labels

Chemical Component Summary
Name	2-chloro-2'-deoxyadenosine
Systematic Name (OpenEye OEToolkits)	(2R,3S,5R)-5-(6-amino-2-chloro-purin-9-yl)-2-(hydroxymethyl)oxolan-3-ol
Formula	C₁₀ H₁₂ Cl N₅ O₃
Molecular Weight	285.687
Type	NON-POLYMER

Chemical Descriptors
Type	Program	Version	Descriptor
SMILES	ACDLabs	10.04	Clc1nc(c2ncn(c2n1)C3OC(C(O)C3)CO)N
SMILES	CACTVS	3.341	Nc1nc(Cl)nc2n(cnc12)[CH]3C[CH](O)[CH](CO)O3
SMILES	OpenEye OEToolkits	1.5.0	c1nc2c(nc(nc2n1C3CC(C(O3)CO)O)Cl)N
Canonical SMILES	CACTVS	3.341	Nc1nc(Cl)nc2n(cnc12)[C@H]3C[C@H](O)[C@@H](CO)O3
Canonical SMILES	OpenEye OEToolkits	1.5.0	c1nc2c(nc(nc2n1[C@H]3C[C@@H]([C@H](O3)CO)O)Cl)N
InChI	InChI	1.03	InChI=1S/C10H12ClN5O3/c11-10-14-8(12)7-9(15-10)16(3-13-7)6-1-4(18)5(2-17)19-6/h3-6,17-18H,1-2H2,(H2,12,14,15)/t4-,5+,6+/m0/s1
InChIKey	InChI	1.03	PTOAARAWEBMLNO-KVQBGUIXSA-N

Drug Info: DrugBank

DrugBank ID	DB00242
Name	Cladribine
Groups	investigational approved
Description	Cladribine is a purine analogue or a chlorinated derivative of adenine [A263733] that causes apoptosis of B and T lymphocytes.[A350] Cladribine was first approved in the United States in 1993 [A263713] initially as a treatment for a number of hematological malignancies; currently, it is approved for the treatment of hairy cell leukemia.[A263733] In 2017 in Europe and in 2019 in the United States, cladribine was also approved for the treatment multiple sclerosis.[A263718]
Synonyms	2ClAdo 2-chloro-6-amino-9-(2-deoxy-β-D-erythro-pentofuranosyl)purine Cladribina 2-Chloro-2'-deoxyadenosine 2-chloro-2′-deoxy-adenosine (2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol 2-CdA 2-chloro-deoxyadenosine 2-Chlorodeoxyadenosine Cladribine 2-Chloro-2'-deoxy-beta-adenosine Cladribinum CldAdo
Brand Names	Leustatin Leustatin 1mg/ml Cladribine Injection Mavenclad Litak Cladribine
Indication	Intravenous cladribine is indicated for the treatment of active Hairy Cell Leukemia as defined by clinically significant anemia, neutropenia, thrombocytopenia or disease-related symptoms.[L50693] Oral cladribine is indicated for the treatment of relapsing forms of multiple sclerosis (MS), including relapsing-remitting disease and active secondary progressive disease, in adults. Because of its safety profile, the use of cladribine is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, an alternate drug indicated for the treatment of MS.[L50688, L50708]
Categories	2-Chloroadenosine Agents Causing Muscle Toxicity Antimetabolites Antineoplastic Agents Antineoplastic and Immunomodulating Agents BCRP/ABCG2 Substrates Cardiotoxic antineoplastic agents Deoxyadenosines Deoxyribonucleosides Heterocyclic Compounds, Fused-Ring Immunologic Factors Immunosuppressive Agents Myelosuppressive Agents Nucleic Acids, Nucleotides, and Nucleosides Nucleosides P-glycoprotein substrates Purine Analogues Purine Antimetabolite Purine Nucleosides Purines Ribonucleosides Selective Immunosuppressants
ATC-Code	L04AA40 L01BB04
CAS number	4291-63-8

Drug Targets

Name	Target Sequence	Pharmacological Action	Actions
Ribonucleoside-diphosphate reductase large subunit	MHVIKRDGRQERVMFDKITSRIQKLCYGLNMDFVDPAQITMKVIQGLYSG...	unknown	inhibitor
Adenosine deaminase	MAQTPAFDKPKVELHVHLDGSIKPETILYYGRRRGIALPANTAEGLLNVI...	unknown	inhibitor
Ribonucleoside-diphosphate reductase subunit M2	MLSLRVPLAPITDPQQLQLSPLKGLSLVDKENTPPALSGTRVLASKTARR...	unknown	inhibitor
Ribonucleoside-diphosphate reductase subunit M2 B	MGDPERPEAAGLDQDERSSSDTNESEIKSNEEPLLRKSSRRFVIFPIQYP...	unknown	inhibitor
DNA	-	unknown	other/unknown,disruptor
DNA polymerase alpha catalytic subunit	MAPVHGDDSLSDSGSFVSSRARREKKSKKGRQEALERLKKAKAGEKYKYE...	unknown	inhibitor
DNA polymerase epsilon catalytic subunit A	MSLRSGGRRRADPGADGEASRDDGATSSVSALKRLERSQWTDKMDLRFGF...	unknown	inhibitor
DNA polymerase epsilon subunit 2	MAPERLRSRALSAFKLRGLLLRGEAIKYLTEALQSISELELEDKLEKIIN...	unknown	inhibitor
DNA polymerase epsilon subunit 3	MAERPEDLNLPNAVITRIIKEALPDGVNISKEARSAISRAASVFVLYATS...	unknown	inhibitor
DNA polymerase epsilon subunit 4	MAAAAAAGSGTPREEEGPAGEAAASQPQAPTSVPGARLSRLPLARVKALV...	unknown	inhibitor
Purine nucleoside phosphorylase	MENGYTYEDYKNTAEWLLSHTKHRPQVAIICGSGLGGLTDKLTQAQIFDY...	unknown	inducer
Poly [ADP-ribose] polymerase 1	MAESSDKLYRVEYAKSGRASCKKCSESIPKDSLRMAIMVQSPMFDGKVPH...	unknown	inducer
Deoxycytidine kinase	MATPPKRSCPSFSASSEGTRIKKISIEGNIAAGKSTFVNILKQLCEDWEV...	unknown	substrate
Deoxyguanosine kinase, mitochondrial	MAAGRLFLSRLRAPFSSMAKSPLEGVSSSRGLHAGRGPRRLSIEGNIAVG...	unknown	substrate
Broad substrate specificity ATP-binding cassette transporter ABCG2	MSSSNVEVFIPVSQGNTNGFPATASNDLKAFTEGAVLSFHNICYRVKLKS...	unknown	substrate
Solute carrier family 28 member 3	MELRSTAAPRAEGYSNVGFQNEENFLENENTSGNNSIRSRAVQSREHTNT...	unknown	substrate
ATP-dependent translocase ABCB1	MDLEGDRNGGAKKKNFFKLNNKSEKDKKEKKPTVSVFSMFRYSNWLDKLY...	unknown	substrate
Equilibrative nucleoside transporter 1	MTTSHQPQDRYKAVWLIFFMLGLGTLLPWNFFMTATQYFTNRLDMSQNVS...	unknown
View More

Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682